Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vivanza BiosciencesBOM:530057 -4.52%53 PB Ratio is 1.74 as of Aug. 16, 2026, which is 73% below its 10-year median of 6.44. GuruFocus rates BOM:530057 with a GF Score™ of 53/100 and a GF Value™ of ₹26.79 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 923 Drug Manufacturers companies, Vivanza Biosciences ranks better than 55.8% on this metric.
The historical rank and industry rank for Vivanza Biosciences's PB Ratio or its related term are showing as below:
BOM:530057'
s PB Ratio Range Over the Past 10 Years
Min: 1.56 Med: 6.44 Max: 26.32
Current: 1.74
During the past 13 years, Vivanza Biosciences's highest PB Ratio was 26.32. The lowest was 1.56. And the median was 6.44.
BOM:530057's PB Ratio is ranked better than 55.8% of 923
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs BOM:530057: 1.74
During the past 12 months, Vivanza Biosciences's average Book Value Per Share Growth Rate was 10.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 2.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 6.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 11.80% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vivanza Biosciences was 176.80% per year. The lowest was -55.50% per year. And the median was 2.10% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vivanza Biosciences PB Ratio Related Terms
Vivanza Biosciences PB Ratio Historical Data
* Premium members only.
The historical data trend for Vivanza Biosciences's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vivanza Biosciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vivanza Biosciences PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vivanza Biosciences's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vivanza Biosciences's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vivanza Biosciences (BOM:530057) has a PB Ratio of 1.74 as of Aug. 16, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivanza Biosciences and its competitors. This is 73% below median its historical median of 6.44. Over the past decade, Vivanza Biosciences' PB Ratio has ranged from 1.56 to 26.32. According to the industry distribution chart, Vivanza Biosciences ranks #408 out of 923 companies in the Drug Manufacturers industry, placing it in the top 44.2%.
Is Vivanza Biosciences' PB Ratio too high?
Vivanza Biosciences' current PB Ratio of 1.74 is 73% below median its 10-year median of 6.44. Over the past 10 years, this metric has ranged from a low of 1.56 to a high of 26.32. The Drug Manufacturers industry median PB Ratio is 1.97. Vivanza Biosciences' value of 1.74 is 11.7% below this industry median. Based on the distribution chart, Vivanza Biosciences ranks #408 out of 923 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Vivanza Biosciences has a GF Score™ of 53/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vivanza Biosciences' PB Ratio compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vivanza Biosciences ranks #408 out of 923 companies for PB Ratio. This puts Vivanza Biosciences in the upper half of its industry. The industry median PB Ratio is 1.97. Vivanza Biosciences' value of 1.74 is 11.7% below this benchmark. Historically, Vivanza Biosciences' own PB Ratio has ranged from 1.56 to 26.32 over the past decade. While the company's 10-year median is 6.44 vs. the industry median of 1.97, Vivanza Biosciences has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.97, based on 923 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vivanza Biosciences's current PB Ratio of 1.74 is 11.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vivanza Biosciences and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vivanza Biosciences's current PB Ratio is 1.74, which is 73% below median its own 10-year median of 6.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vivanza Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Vivanza Biosciences (BOM:530057) is currently considered Possible Value Trap. The stock's GF Value™ is ₹26.79, compared to a current price of ₹1.90 — trading 92.9% below its estimated fair value. The current PB Ratio is 1.74, which is 73% below median its 10-year median of 6.44 and 11.7% below the Drug Manufacturers industry median of 1.97. Vivanza Biosciences' overall GF Score™ is 53/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vivanza Biosciences (BOM:530057), the current PB Ratio is 1.74 as of Aug. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vivanza Biosciences (BOM:530057) Overvalued in 2026?
Based on GuruFocus' analysis, Vivanza Biosciences stock appears to be undervalued.
The current stock price of ₹1.90 is trading 92.9% below its estimated GF Value™ of ₹26.79.
GuruFocus considers Vivanza Biosciences to be Possible Value Trap.
Key valuation signals for BOM:530057:
PB Ratio: 1.74 (73% below median its 10-year median of 6.44)
GF Value™: ₹26.79 vs. price of ₹1.90 (92.9% below fair value)
Industry Position: 11.7% below the Drug Manufacturers median (#408 of 923)
No single metric tells the full story. See the BOM:530057 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vivanza Biosciences Ltd is a pharmaceutical company. Its core focus areas include research and development, manufacturing, and the distribution of a wide range of pharma and pharmaceutical products. The company's product portfolio includes Medical examination gloves, Injections, Veterinary feeds, and others.
53GF Score
Get the complete analysis for BOM:530057
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:530057 has been successfully added to your 
